A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
- Sponsor:
- Gilead Sciences, Inc.
- Sponsor Study ID:
- GS-US-682-6769 AND/OR GOG-3104/ENGOT-en26
- CTO #:
- 104078
- NCT Number:
- NCT06486441
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Other Female Genital
- Study Objectives:
- To compare the effect of sacituzumab govitecan (SG) relative to treatment of physician s choice (TPC) on progression-free survival (PFS) as assessed by blinded independent central review (BICR). To compare the effect of SG relative to TPC on overall survival (OS).
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Orr, Brian, at orrb@musc.edu .
- Study Coordinator, Knox, Crystal, at knoxc@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina